BioVie (BIVI) AI Stock Analysis

• Market Cap: $20.43M
• Dividend Yield: N/A
• Average Volume (3M): 663.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: N/A
• EPS Growth: 66.72%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -3.95
• Shares Outstanding: 18,570,726
• 10 Day Avg. Volume: 202,325
• 30 Day Avg. Volume: 663,056
• PEG Ratio: -0.12
• Price to Book (P/B): 18.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.96
• Enterprise Value/Market Cap: 2.94
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -261.47
• Enterprise Value/Ebitda: -0.64
• 1Y Price Target: $6.00
• Price Target Upside: 404.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 38 Underperform
• Price Target: ―

BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.

BioVie Business Overview & Revenue Model

Company Description

BioVie Inc. (BIVI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver disease, specifically targeting unmet medical needs in the treatment of chronic liver disorders and neurological conditions. The company's core products include NE3107, a novel molecule aimed at treating Alzheimer's and Parkinson's diseases, and BIV201, an innovative treatment for ascites due to liver cirrhosis.

How the Company Makes Money

BioVie primarily makes money through the development and eventual commercialization of its pharmaceutical products. The company seeks to generate revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and partnering with larger pharmaceutical companies for distribution and marketing. Significant partnerships with research institutions and pharmaceutical firms play a crucial role in funding research and development efforts. Additionally, BioVie may earn revenue through milestone payments and royalties as its products move closer to market availability and achieve commercial success.

BioVie Financial Statement Overview

Summary

BioVie is in the pre-commercialization phase with no revenue generation and high net losses. The company relies heavily on equity financing, as indicated by a strong equity position and minimal debt. However, the ongoing cash burn in R&D activities highlights significant financial risks.

Income Statement

BioVie shows consistent negative gross profit and net income, with no revenue generation, which is typical for early-stage biotech companies. The ongoing net losses and negative EBIT and EBITDA margins indicate a company still in the R&D phase without product commercialization. Growth metrics are not applicable due to zero revenue.

Balance Sheet

The balance sheet reflects a relatively high stockholders' equity and minimal debt, leading to a favorable debt-to-equity ratio. However, the company's equity ratio suggests reliance on equity financing, typical for biotech firms. The improving equity position is a positive sign, but the lack of tangible assets remains a concern.

Cash Flow

BioVie has negative operating and free cash flows, indicative of high cash burn in R&D activities. There is significant reliance on financing cash flows to maintain operations. The lack of positive cash flow metrics highlights the company's current inability to generate cash from operations.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-229.38K	-229.00K	-267.00K	-237.00K	-229.00K	-229.00K
	EBIT
-19.19M	-32.18M	-45.08M	-27.25M	-138.05M	-2.69M
	EBITDA
-18.30M	-31.95M	-45.69M	-26.98M	-137.80M	-2.46M
	Net Income Common Stockholders
-19.04M	-32.12M	-50.26M	-26.08M	-130.25M	-16.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.15M	23.84M	33.94M	18.64M	4.51M	37.20K
	Total Assets
24.66M	25.21M	35.10M	20.11M	6.05M	2.08M
	Total Debt
366.43K	6.11M	14.42M	12.26M	0.00	911.04K
	Net Debt
-22.79M	-17.73M	-5.04M	-6.38M	-4.51M	873.85K
	Total Liabilities
2.84M	9.70M	19.76M	16.44M	996.37K	23.58M
	Stockholders Equity
21.82M	15.51M	15.34M	3.67M	5.05M	-21.50M
Cash Flow		Free Cash Flow
-17.42M	-27.95M	-40.25M	-18.99M	-10.45M	-1.63M
	Operating Cash Flow
-17.42M	-27.95M	-40.25M	-18.99M	-10.45M	-1.63M
	Investing Cash Flow
0.00	14.53M	-14.30M	0.00	0.00	0.00
	Financing Cash Flow
10.23M	17.80M	55.37M	33.12M	14.93M	1.33M

BioVie Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.19
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIVI, the sentiment is Positive. The current price of 1.19 is above the 20-day moving average (MA) of 1.07, above the 50-day MA of 0.98, and below the 200-day MA of 1.81, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 62.68 is Neutral, neither overbought nor oversold. The STOCH value of 70.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIVI.

BioVie Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
LPCN	48 Neutral	$17.66M	650.59	-24.89%	―	10081.34%	―
CING	47 Neutral	$19.66M	―	-358.06%	―	―	95.52%
CANF	42 Neutral	$15.33M	―	-122.28%	―	―	―
BIVI	38 Underperform	$20.43M	―	-93.23%	―	―	66.72%
EDSA	35 Underperform	$13.06M	―	-58.78%	―	―	-126.54%
UBX	31 Underperform	$15.14M	―	-231.27%	―	―	35.08%

BioVie Corporate Events

BioVie Raises $3.24 Million in Direct Offering

BioVie Inc. announced the successful closing of its registered direct offering, raising $3.24 million by selling 1,146,000 shares of its common stock at $2.83 per share. The funds will primarily be used for working capital and corporate purposes. As a clinical-stage company, BioVie is developing innovative therapies for chronic conditions like liver disease and neurodegenerative disorders, with promising drug candidates in the pipeline.

BioVie Raises Capital Through Direct Stock Offering

BioVie Inc. has launched a registered direct offering, selling 1,146,000 shares of its common stock at $2.83 per share, aiming to raise approximately $3.2 million. The proceeds will be used primarily for working capital and general corporate purposes. The offering, managed by ThinkEquity, is set to close on October 29, 2024, and is made under a shelf registration statement filed with the SEC.

BioVie Raises $6 Million in Strategic Funding

BioVie Inc., a clinical-stage company developing treatments for chronic conditions, has successfully closed a direct offering and private placement, raising approximately $6 million. The funds will be primarily used for working capital and general corporate purposes. This strategic financial move reflects BioVie’s ongoing commitment to advancing its innovative drug therapies, including those for neurodegenerative disorders and liver disease, amidst market uncertainties and potential risks.

BioVie Announces $6 Million Stock Offering and Placement

BioVie Inc., a clinical-stage company, has announced a registered direct offering and concurrent private placement, pricing 2,667,000 shares of its common stock at $2.25 per share, with unregistered warrants allowing purchase of additional shares at $2.12 each. This deal, facilitated by ThinkEquity, aims to raise approximately $6 million before expenses, with proceeds earmarked for working capital and corporate purposes. The offering is set to close around October 24, 2024, pending customary conditions.

BioVie Secures $6.66 Million Through Direct Offering

BioVie Inc. has announced the successful closing of a registered direct offering and concurrent private placement, raising gross proceeds of approximately $6.66 million. The offering included 4,443,000 shares of common stock at $1.50 per share and warrants for the same number of shares at an exercise price of $1.37 per share. The company plans to use the funds for working capital and corporate purposes. This development is significant for investors tracking BioVie’s financial maneuvers and potential growth in the biopharmaceutical sector.

BioVie Announces Stock Offering and Private Placement

BioVie Inc. announced a direct stock offering and a private placement, aiming to raise approximately $6.66 million through the sale of shares at $1.50 each. Additionally, the company will issue warrants exercisable for shares at $1.37 per share. These funds are intended for working capital and corporate purposes, with the offering closing expected on October 22, 2024. The company is focused on developing treatments for liver and neurological diseases.